Story perspectives

Vertex Pharmaceuticals Poised for Growth with New Therapies

10/10/2025

Summary

Story summary

Vertex Pharmaceuticals is set for growth with a robust pipeline and upcoming regulatory approvals.
The company plans to file for global approval of its islet cell therapy, zimislecel, for severe type 1 diabetes in 2024.
Vertex seeks accelerated approval for povetacicept targeting IgA nephropathy and is exploring Journavx for diabetic peripheral neuropathy.
Its existing therapies, including the first CRISPR gene-editing treatment for sickle cell disease, strengthen its market position.
Vertex's low price-to-earnings ratio indicates an attractive valuation in a challenging market.

1 of 1

Story summary

Vertex Pharmaceuticals is set for growth with a robust pipeline and upcoming regulatory approvals.
The company plans to file for global approval of its islet cell therapy, zimislecel, for severe type 1 diabetes in 2024.
Vertex seeks accelerated approval for povetacicept targeting IgA nephropathy and is exploring Journavx for diabetic peripheral neuropathy.
Its existing therapies, including the first CRISPR gene-editing treatment for sickle cell disease, strengthen its market position.
Vertex's low price-to-earnings ratio indicates an attractive valuation in a challenging market.